<DOC>
	<DOCNO>NCT01888471</DOCNO>
	<brief_summary>Feasibility phase study evaluate antibody level Group B Streptococcus mother infant delivery establish antibody level associate reduction risk GBS disease infant age less 90 day .</brief_summary>
	<brief_title>Feasibility Study Identifying Antibody Levels Associated With Reduced Risk Invasive Group B Streptococcus Disease Young Infants .</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>( ) Pregnant woman attend antenatal clinic one participate antenatalclinics and/or deliver one participate delivery center . ( ii ) Subjects age â‰¥18 year . ( iii ) Able understand comply plan study procedure . ( iv ) Provides write informed consent . ( ) Refuses consent study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>serotype specific</keyword>
	<keyword>anti-capsular antibody</keyword>
	<keyword>Group B Streptococcus</keyword>
	<keyword>Feasibility</keyword>
</DOC>